Agios Pharmaceuticals (AGIO) - Get Agios Pharmaceuticals, Inc. Report was upgraded to overweight from neutral at JPMorgan. $62 price target. Expect better PKD and hematology clinical data, JPMorgan said.
Agios Pharmaceuticals was upgraded to buy from hold at Canaccord Genuity. $90 price target. PKD treatment is showing meaningful clinical progress, Canaccord said.
Axiall (AXLL) was downgraded to neutral from overweight at JPMorgan. The valuation is less attractive, based on a $33 price target, JPMorgan said.
Concho Resources (CXO) - Get Concho Resources Inc. Report was upgraded to overweight at Morgan Stanley. $173 price target. The company has long-term oil exposure with significant upside growth potential, Morgan Stanley said.
ON Semiconductor (ON) - Get ON Semiconductor Corporation Report was upgraded to overweight at Pacific Crest. $13 price target. The company should see higher incremental ADAS content and synergies from the Fairchild purchase, Pac Crest said.
Occidental Petroleum (OXY) - Get Occidental Petroleum Corporation Report was downgraded to equal-weight from overweight at Morgan Stanley. The valuation is less attractive, based on $70 price target, Morgan Stanley said.
PRA Health (PRAH) - Get PRA Health Sciences, Inc. Report was upgraded to overweight at Keybanc. $55 price target. Management is reducing structural overhangs and will likely boost guidance, Keybanc said.
This article was written by a staff member of TheStreet.